CYCLOSET Drug Patent Profile

When do Cycloset patents expire, and what generic alternatives are available?

Cycloset is a drug marketed by Veroscience and is included in one NDA. There are thirteen patents protecting this drug.

This drug has thirty-four patent family members in thirteen countries.

The generic ingredient in CYCLOSET is bromocriptine mesylate. There are nine drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the bromocriptine mesylate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Cycloset

A generic version of CYCLOSET was approved as bromocriptine mesylate by SANDOZ on January 13^th, 1998.

Summary for CYCLOSET

International Patents:	34
US Patents:	13
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for CYCLOSET

CYCLOSET is protected by one hundred and twenty-six US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Veroscience	CYCLOSET	bromocriptine mesylate	TABLET;ORAL	020866-001	May 5, 2009		RX	Yes	Yes
Veroscience	CYCLOSET	bromocriptine mesylate	TABLET;ORAL	020866-001	May 5, 2009		RX	Yes	Yes			Y
Veroscience	CYCLOSET	bromocriptine mesylate	TABLET;ORAL	020866-001	May 5, 2009		RX	Yes	Yes

International Patents for CYCLOSET

See the table below for patents covering CYCLOSET around the world.

Country	Patent Number	Title	Estimated Expiration
Czech Republic	282909	Použití agonisty dopaminu a stimulátoru prolaktinu pro přípravu farmaceutického přípravku a tento farmaceutický přípravek (THE USE OF DOPAMINE AGONISTIC, PROLACTIN INHIBITING COMPOUND)
Greece	3029276
Germany	69535996

Analysis of CYCLOSET: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

---

Summary

CYCLOSET (cyproterone acetate and estradiol) is a combination hormone therapy primarily indicated for contraception and hormone-responsive conditions. As a well-established pharmaceutical, its market positioning depends on regulatory stability, patent landscape, competitive dynamics, and emerging therapeutic indications. This report examines key investment considerations, market factors, and financial projections associated with CYCLOSET, providing an integrated evaluation for stakeholders and investors.

---

1. Overview of CYCLOSET: Product Profile and Regulatory Status

Aspect	Details
Active Ingredients	Cyproterone acetate, Ethinyl estradiol (original formulations include similar components, but CYCLOSET specifically is known for cyproterone acetate + estradiol)
Therapeutic Indications	Contraception, hormone therapy for androgen-related conditions, hormone-sensitive tumors (e.g., prostate cancer)
Formulation	Oral tablets (varying dosages, e.g., 2 mg/0.035 mg)
Market Authorization & Approvals	Approved across multiple regions (EU, US, Asia) with varying patent statuses (many generic versions available)
Patents & Exclusivity	Patent exclusivity generally expired or nearing expiry; more protected in certain jurisdictions (e.g., patent extensions or proprietary formulations)

---

2. Investment Scenario Analysis

A. Market Demand & Revenue Potential

Parameter	Estimate / Range	Notes
Global contraceptive market size (2022)	~$22 billion	CAGR ~6.4% (2023-2030) [1]
Market share for combined hormonal contraceptives (CHCs)	~50%	Cost and familiarity favor CHC formulations
Estimated market penetration for CYCLOSET (contraceptive segment)	10-15%	Based on competition, brand recognition
Annual sales per region (e.g., US, EU)	$100-300 million (per region)	Depending on market penetration
Expected CAGR (2023-2030)	4-7%	Driven by expanding contraceptive needs, aging populations, and emerging markets

B. Patent & Regulatory Landscape

Aspect	Details
Patent Duration & Expiry	Key patents expired or set to expire (e.g., US patents expired ~2018-2020) [2]
Market Exclusivity Opportunities	Limited; secondary patents or formulation patents may extend exclusivity
Regulatory Barriers	Good Manufacturing Practice (GMP) compliance, regional approvals, potential patent challenges

C. Competitive Environment

Major Competitors	Market Position	Strengths / Weaknesses
Generic Hormonal Contraceptives	Dominant	Lower cost, broad availability
Brand Name Contraceptives (Yaz, Yasmin)	Moderate	Brand loyalty, clinical data
Emerging Long-Acting Reversible Contraceptives (LARCs)	Increasing	Less frequent dosing, market shift

---

3. Market Dynamics and Trends

A. Growth Drivers

Drivers	Impact & Notes
Rising global contraceptive demand	Driven by population growth, women’s health initiatives
Regulatory approvals in emerging markets	Expanding access increases sales opportunities
Increasing awareness for hormone therapy	Ageing populations increasing demand for hormone regulation

B. Market Restraints and Risks

Restraints	Impact & Notes
Patent expiries	Leads to increased competition from generics
Market saturation	Mature markets limit growth prospects
Regulatory challenges	Variations across regions in approvals and registration processes

C. Potential Therapeutic and Indication Expansion

Opportunities	Details
Use in hormone-responsive tumors	Off-label or new indications could drive growth
Long-acting formulations	Extended-release variants could capture additional market share
Combination with novel agents	Opportunities for co-therapies with emerging treatments

---

4. Financial Trajectory Projections

A. Revenue Forecast (2023-2030)

Year	Estimated Revenue (USD M)	Growth Rate (%)	Assumptions
2023	150	—	Entry into emerging markets, stable US/EU sales
2024	160	+6.7	Increased market penetration
2025	170	+6.3	Market expansion, approvals mid-year
2026	180	+5.9	Competition stabilizes
2027	190	+5.6	Slight growth from new indications
2028	200	+5.3	Mature market plateau
2029	210	+5.0	Entry of biosimilars/generics
2030	220	+4.8	Market maturity

B. Cost Structure and Profitability Estimates

Parameter	USD Million (per annum)	Notes
R&D Expenses	10-15	Focused on new formulations, indications
Manufacturing Costs	30-40	Economies of scale, regional variances
Regulatory & Marketing	25-35	Launch campaigns, compliance
Net Margin Estimate	15-25%	Post-expiry generic competition pressures

C. Investment Considerations

• Market Penetration Potential: High in emerging markets due to low-cost options, moderate in mature markets.
• Patent Strategies: Securing secondary patents or formulations could extend exclusivity.
• Therapeutic Expansion: R&D into long-acting or novel indications could boost revenue.
• Pricing & Insurance Policies: Reimbursement strategies influence margins, especially in different jurisdictions.

---

5. Comparison with Similar Market Players

Product	Active Ingredients	Market Share (Approx.)	Patents	Key Differentiator
Yaz (Bayer)	Ethinyl estradiol + Drospirenone	10-15% in US contraceptive market	Patent expired 2020	Limited side effects, extended indications
Yasmin (Bayer)	Ethinyl estradiol + Drospirenone	Similar to Yaz	Patent expired	Well-established brand presence
Generic versions	Cyproterone acetate + Estradiol	>50%	Expired	Cost advantage

---

6. Regulatory Pathways and Policy Environment

Region	Key Policies	Impact on Investment
United States	FDA regulations, ANDA pathway for generics	Patent expiry accelerates generics; future clinical trials for new indications possible
European Union	EMA approval processes	Stringent but predictable; early adoption possible
Asia-Pacific	Registration via local authorities, varying approval standards	Expanding market, lower barriers

---

Key Takeaways

• Patent expiry, combined with increasing generic competition, has started to compress profit margins for CYCLOSET, but opportunities exist in emerging markets, formulation innovation, and new indications.
• Market growth driven by global contraceptive demand and aging populations provides a positive long-term trajectory, with CAGR projected around 4-7% globally.
• Pricing strategies and regulatory navigation are critical to maintaining revenue streams, especially as patent protections wane.
• Therapeutic expansion into hormonal tumor treatments and long-acting formulations can serve as future revenue catalysts.
• Competitive landscape favors cost-advantaged generics, but brand loyalty and differentiated formulations could preserve premium pricing segments.

---

FAQs

Q1: What are the primary factors influencing CYCLOSET’s market share?
A1: Patent status, regional regulatory approvals, clinician preferences, and the availability of cheaper generics significantly influence its market share.

Q2: How does patent expiry impact CYCLOSET’s revenue prospects?
A2: Patent expiration opens the market to generic competitors, leading to price erosion and reduced margins; strategic patent extensions or formulation innovations can mitigate this impact.

Q3: Which emerging indications could bolster CYCLOSET’s market value?
A3: Use in hormone-responsive tumors, aging-related hormone therapy, and long-acting formulations are potential expansion avenues.

Q4: How do regional policies affect the investment outlook?
A4: Stringent regulatory environments like the US and EU may delay or limit growth but also protect existing market share; emerging markets present growth opportunities with evolving policies.

Q5: What are the main risks in investing in CYCLOSET-based formulations?
A5: Patent cliffs, high dependency on regulatory approvals, pricing pressures from generics, and competition from new contraceptive technologies.

---

References

[1] Grand View Research, "Contraceptive Market Size & Trends (2022-2030)", 2022.
[2] U.S. Patent and Trademark Office, Patent expirations related to hormonal contraceptives, 2021.